190 related articles for article (PubMed ID: 27665170)
1. Amyloidogenesis of the amylin analogue pramlintide.
da Silva DC; Fontes GN; Erthal LC; Lima LM
Biophys Chem; 2016 Dec; 219():1-8. PubMed ID: 27665170
[TBL] [Abstract][Full Text] [Related]
2. Physico-chemical properties of co-formulated fast-acting insulin with pramlintide.
da Silva DC; Lima LMTR
Int J Pharm; 2018 Aug; 547(1-2):621-629. PubMed ID: 29928940
[TBL] [Abstract][Full Text] [Related]
3. Stepwise oligomerization of murine amylin and assembly of amyloid fibrils.
Palmieri LC; Melo-Ferreira B; Braga CA; Fontes GN; Mattos LJ; Lima LM
Biophys Chem; 2013; 180-181():135-44. PubMed ID: 23974296
[TBL] [Abstract][Full Text] [Related]
4. Zn(II) - pramlintide: Stability, binding sites and unexpected aggregation.
Łoboda D; Rowińska-Żyrek M
J Inorg Biochem; 2017 Sep; 174():150-155. PubMed ID: 28672144
[TBL] [Abstract][Full Text] [Related]
5. Regulation of the assembly and amyloid aggregation of murine amylin by zinc.
Erthal LC; Marques AF; Almeida FC; Melo GL; Carvalho CM; Palmieri LC; Cabral KM; Fontes GN; Lima LM
Biophys Chem; 2016 Nov; 218():58-70. PubMed ID: 27693831
[TBL] [Abstract][Full Text] [Related]
6. Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Gingell JJ; Burns ER; Hay DL
Endocrinology; 2014 Jan; 155(1):21-6. PubMed ID: 24169554
[TBL] [Abstract][Full Text] [Related]
7. Be positive: optimizing pramlintide from microcanonical analysis of amylin isoforms.
Frigori RB
Phys Chem Chem Phys; 2017 Sep; 19(37):25617-25633. PubMed ID: 28905065
[TBL] [Abstract][Full Text] [Related]
8. The dye SYPRO orange binds to amylin amyloid fibrils but not pre-fibrillar intermediates.
Wong AG; Raleigh DP
Protein Sci; 2016 Oct; 25(10):1834-40. PubMed ID: 27479186
[TBL] [Abstract][Full Text] [Related]
9. Pramlintide (Amylin).
Barlocco D
Curr Opin Investig Drugs; 2001 Nov; 2(11):1575-81. PubMed ID: 11763160
[TBL] [Abstract][Full Text] [Related]
10. Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus.
Nyholm B; Brock B; Ørskov L; Schmitz O
Expert Opin Investig Drugs; 2001 Sep; 10(9):1641-52. PubMed ID: 11772274
[TBL] [Abstract][Full Text] [Related]
11. Human Amylin: From Pathology to Physiology and Pharmacology.
Ling W; Huang YM; Qiao YC; Zhang XX; Zhao HL
Curr Protein Pept Sci; 2019; 20(9):944-957. PubMed ID: 30919775
[TBL] [Abstract][Full Text] [Related]
12. Nephrectomy decreases amylin and pramlintide clearance in rats.
Vine W; Smith P; LaChappell R; Blase E; Lumpkin R; Young A
Horm Metab Res; 1998 Aug; 30(8):514-7. PubMed ID: 9761382
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.
Adler BL; Yarchoan M; Hwang HM; Louneva N; Blair JA; Palm R; Smith MA; Lee HG; Arnold SE; Casadesus G
Neurobiol Aging; 2014 Apr; 35(4):793-801. PubMed ID: 24239383
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human islet amyloid polypeptide or amylin aggregation by two manganese-salen derivatives.
Bahramikia S; Yazdanparast R
Eur J Pharmacol; 2013 May; 707(1-3):17-25. PubMed ID: 23528352
[TBL] [Abstract][Full Text] [Related]
15. Effects of amylin and the amylin agonist pramlintide on glucose metabolism.
Schmitz O; Nyholm B; Orskov L; Gravholt C; Møller N
Diabet Med; 1997 Jun; 14 Suppl 2():S19-23. PubMed ID: 9212325
[TBL] [Abstract][Full Text] [Related]
16. The toxic nature of murine amylin and the immune responsivity of pancreatic islet to conformational antibody in mice.
Erthal LCS; Jotha-Mattos L; Lara FA; Dos Reis SA; de Oliveira Pascarelli BM; Costa CM; Souza KLA; Lima LMTR
Mol Cell Biochem; 2018 Oct; 447(1-2):1-7. PubMed ID: 29372531
[TBL] [Abstract][Full Text] [Related]
17. Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility.
Wang H; Abedini A; Ruzsicska B; Raleigh DP
Biochemistry; 2014 Sep; 53(37):5876-84. PubMed ID: 25140605
[TBL] [Abstract][Full Text] [Related]
18. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus.
Borm AK; Klevesath MS; Borcea V; Kasperk C; Seibel MJ; Wahl P; Ziegler R; Naworth PP
Horm Metab Res; 1999 Aug; 31(8):472-5. PubMed ID: 10494873
[TBL] [Abstract][Full Text] [Related]
19. Physico-chemical stability of co-formulation of PEGylated human amylin with insulin.
Sinésia C; do Nascimento CVMF; Lacativa PGS; Lima LMTR
Pharm Dev Technol; 2019 Oct; 24(8):975-981. PubMed ID: 31124388
[TBL] [Abstract][Full Text] [Related]
20. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.
Kolterman OG
Diabet Med; 1997 Jun; 14 Suppl 2():S35-8. PubMed ID: 9212328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
